| Alternative Names | NFHEV, DKFZp586H0523, DVS27, NFEHEV, RP11-575C20.2 |
| Source | Human IL-33 (C208S,C227S,C232S,C259S) Protein; His Tag (GM-88847RP) is expressed from human 293 cells (HEK-293). It contains AA His109-Thr270 (Accession # O95760-1). This protein carries a His tag at the N-terminus. |
| Purity | > 95% as determined by SDS-PAGE |
| Endotoxin | < 1 EU/μg, determined by LAL gel clotting assay |
| Predicted Mol Mass | 19.1 kDa |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Description | IL-33 protein, full name Interleukin-33, is an important cytokine and a member of the IL-1 superfamily. The IL-33 (C208S, C227S, C232S, C259S) variant is a site-directed mutant form in which four cysteine residues at positions 208, 227, 232, and 259 are replaced by serine residues, designed to enhance protein stability and prevent disulfide bond-mediated aggregation or oxidation. IL-33 protein plays a crucial role in regulating immune responses, inflammation, and tissue homeostasis in normal cells. Currently, therapeutic strategies targeting IL-33 or its receptor ST2 are under clinical investigation, including neutralizing antibodies and receptor antagonists, which aim to block IL-33/ST2 signaling to alleviate inflammatory symptoms and improve disease outcomes in patients with allergic and autoimmune disorders. In summary, IL-33 (C208S, C227S, C232S, C259S) protein plays a critical role in immune regulation and inflammatory diseases, and is of great significance for understanding the pathogenesis of immune-mediated disorders, developing targeted therapeutic interventions, and evaluating patient prognosis. This engineered mutant form provides a more stable and reliable tool for research and therapeutic applications. |
| Alternative Names | NFHEV, DKFZp586H0523, DVS27, NFEHEV, RP11-575C20.2 |
| Source | Human IL-33 (C208S,C227S,C232S,C259S) Protein; His Tag (GM-88847RP) is expressed from human 293 cells (HEK-293). It contains AA His109-Thr270 (Accession # O95760-1). This protein carries a His tag at the N-terminus. |
| Purity | > 95% as determined by SDS-PAGE |
| Endotoxin | < 1 EU/μg, determined by LAL gel clotting assay |
| Predicted Mol Mass | 19.1 kDa |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Description | IL-33 protein, full name Interleukin-33, is an important cytokine and a member of the IL-1 superfamily. The IL-33 (C208S, C227S, C232S, C259S) variant is a site-directed mutant form in which four cysteine residues at positions 208, 227, 232, and 259 are replaced by serine residues, designed to enhance protein stability and prevent disulfide bond-mediated aggregation or oxidation. IL-33 protein plays a crucial role in regulating immune responses, inflammation, and tissue homeostasis in normal cells. Currently, therapeutic strategies targeting IL-33 or its receptor ST2 are under clinical investigation, including neutralizing antibodies and receptor antagonists, which aim to block IL-33/ST2 signaling to alleviate inflammatory symptoms and improve disease outcomes in patients with allergic and autoimmune disorders. In summary, IL-33 (C208S, C227S, C232S, C259S) protein plays a critical role in immune regulation and inflammatory diseases, and is of great significance for understanding the pathogenesis of immune-mediated disorders, developing targeted therapeutic interventions, and evaluating patient prognosis. This engineered mutant form provides a more stable and reliable tool for research and therapeutic applications. |
